Purpose of review Exposure of blood to foreign surfaces induces reciprocal conversion of the plasma proteins factor XII (fXII) and plasma prekallikrein (PPK) to the proteases a-fXIIa and a-kallikrein. This process, called contact activation, has a range of effects on host defence mechanisms, including promoting coagulation. The nature of the triggering mechanism for contact activation is debated. One hypothesis predicts that fXII has protease activity, either intrinsically or upon surface-binding, that initiates contact activation. We tested this by assessing the proteolytic activity of a recombinant fXII variant that cannot be converted to a-fXIIa.
INTRODUCTION
Exposure of blood to a variety of nonbiologic surfaces and substances can lead to formation of a blood clot [1,2 & 
,3
& ,4,5 & ]. Surface-induced coagulation is initiated by a process called contact activation. Contact activation is the first step in clot formation in the activated partial thromboplastin time (aPTT) assay widely used to evaluate plasma thrombin generation [6, 7] . In the aPTT, the plasma protease precursors factor XII (fXII) and plasma prekallikrein (PPK) undergo reciprocal proteolytic conversion to the fully active protease species a-factor XIIa (a-fXIIa) and a-kallikrein (a-kal) on an anionic surface such as silica particles (Fig. 1 ) [8, 9] . The glycoprotein high molecular weight kininogen serves as a cofactor by facilitating PPK binding to the activating surface [10] [11] [12] . a-FXIIa, its degradation product b-FXIIa (Fig. 2) , and a-kal can activate components of host defense processes, including the plasma coagulation and complement systems, inflammation, and fibrinolysis ( Fig. 1 4, 13] . FXII, PPK, and kininogen are also referred to as the kallikrein-kinin system (KKS), because a-kallikrein, among its activities, cleaves kininogen to release the inflammatory peptide bradykinin [2 or pathologic cofactors for the KKS in vivo. It has been proposed that the KKS contributes to the innate host response to invading microorganisms [5 & , [22] [23] [24] [25] . Indeed, a process similar to contact activation may occur when KKS proteins assemble on cell membranes or cell walls of microorganisms, leading to production of bradykinin and antimicrobial peptides by kininogen cleavage [22] [23] [24] [25] . This same capacity to assemble on 'nonself' surfaces likely occurs when blood passes through extracorporeal circuits (cardiopulmonary bypass, extracorporeal membrane oxygenation, renal dialysis) or comes into contact with implantable devices (ventricular assist devices, artificial heart valves, and central venous catheters), contributing to thrombogenicity and inflammation [5 & ,26-31] . Although the major proteolytic reactions involved in contact activation are well described, there is uncertainty as to the event(s) that trigger fXII and PPK activation [32] . Plasma may normally contain traces of a-fXIIa or a-kal that prime the process once a surface is available [33] [34] [35] . Reciprocal fXII and PPK activation seems to occur at a measurable basal level in healthy mice, suggesting a continuous supply of a-fXIIa or a-kal [36] . Proteases from outside the KKS such as prolylcarboxypeptidase (PRCP, activates PPK) [37] [38] [39] and factor XIa (fXIa, activates fXII) [40] may also serve as initiators. Another possibility is that fXII, rather than being a true zymogen (an inactive enzyme precursor), has proteolytic activity or expresses activity after binding to a surface [41] [42] [43] . Binding of certain proteins to the coagulation factor prothrombin (staphylocoagulase, von Willebrand factor binding protein, histone H4) [44] [45] [46] or the fibrinolytic protein plasminogen (streptokinase) [47] can produce conformational changes that confer protease activity on these zymogens. Surface binding may cause a similar effect with fXII. It has been difficult to sort out candidate mechanisms for initiating fXII activation, because it is difficult to exclude the possibility that fXII purified from plasma is contaminated with a-fXIIa. We addressed this recently by studying recombinant fXII variants that are not converted to a-fXIIa. Our work with one of these proteins and the implications of our findings are the subject of this review.
FACTOR XII STRUCTURE
Human fXII is an $80 kDa polypeptide composed of several domains that form a noncatalytic heavy chain and a C-terminal trypsin-like catalytic (light chain) domain (Fig. 2) [13,48 & ] . FXII is expressed in a number of cell types, but the protein that circulates in plasma comes primarily from hepatocytes [32, 49] . The fXII gene has been identified in amphibian, reptile, and mammal genomes, but not in fish, raising the possibility that fXII is adaptive for terrestrial environments [50, 51] . For unknown reasons, the gene has been lost in birds and diving mammals (whales and porpoises). FXII is the result of a duplication event involving the more ancient gene for the protease Pro-hepatocyte growth factor activator (Pro-HGFA, Fig. 2 ) [52, 53] . Activation of Pro-HGFA (by thrombin) to the protease
KEY POINTS
The plasma protein factor XII participates in activation of several host defence mechanisms.
A variety of substances and surfaces support factor XII conversion to its fully active form a-factor XIIa, but the triggering mechanism for this process is not established.
Factor XII has proteolytic activity in its single-chain 'precursor' form that may trigger initial conversion of factor XII to a-factor XIIa when blood is exposed to a surface. FIGURE 1. Contact activation. On a surface (represented by the gray oval), factor XII (fXII) undergoes autocatalytic conversion to the protease a-fXIIa, which in turn converts plasma prekallikrein (PPK) to the protease a-kallikrein (a-Kal). High molecular weight kininogen (HK) serves as a cofactor for contact activation by facilitation the interaction between PPK and the surface. Through their proteolytic capacities, a-fXIIa and a-kal can influence a number of host-defense systems (shown in black ovals). a-FXIIa promotes thrombin generation through conversion of factor XI to factor XIa. aKal can promote inflammation by cleaving HK to liberate the nanopeptide bradykinin.
HGFA, like activation of fXII, is enhanced by surfaces, suggesting these homologs have similar surfacebinding elements [54] . HGFA may be converted to a short form analogous to b-FXIIa [53, 54] . For fXII, several lines of evidence indicate the N-terminal fibronectin type II domain is involved in surface binding, but other studies implicate the fibronectin type I and kringle domains, and the proline-rich region ( Fig. 2) [23, [55] [56] [57] [58] . It is possible that different domains contribute to binding, depending on the type of surface involved.
The organization of exons encoding the Pro-HGFA and fXII catalytic domains indicate homology with the plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA, Fig. 2 ) [54, [59] [60] [61] [62] . Miyazawa et al. [52] proposed that FIGURE 2. Domain organization of factor XII and related proteases. Schematic diagrams showing single chain and cleaved forms of fXII (top), Pro-hepatocyte growth factor activator (Pro-HGFA), and tissue plasminogen activator (tPA) Sites of proteolysis during activation are indicated by arrows, with the numbers indicating the residue after which cleavage occurs. FXII is an 80 kDa polypeptide that may be cleaved at three locations. Cleavage after Arg353 converts fXII to a-fXIIa. Cleavage of a-fXIIa after Arg334 separates the noncatalytic and catalytic domains, forming bFXIIa. The importance of cleavage after Arg343 is not clear. The fXII noncatalytic domains are the fibronectin type 2 (F2), epidermal growth factor (EGF), fibronectin type 1 (F1), and kringle (K) domains, and proline-rich region (PRR). Pro-HGFA is converted to HGFA by cleavage after Arg407. It can also be converted to a short form, similar to bFXIIa, by cleavage after Arg372. It has similar domain structure to fXII except that it lacks the PRR. Single chain tissue plasminogen activator (sc-tPA) is converted to two chain tPA (tc-tPA) by cleavage after Arg275. Its noncatalytic portion contains domains similar to those found in fXII and Pro-HGFA.
fXII, Pro-HGFA, tPA, and uPA form a protease family. tPA and uPA express substantial proteolytic activity in their single-chain forms, a property referred to as low zymogenicity [63, 64] . Trypsin-like proteases are usually secreted as inactive singlechain zymogens that require internal proteolysis after Arg15 (chymotrypsin numbering) for activity [65] . After cleavage, the new N-terminus of the catalytic domain (residue 16) forms a salt-bridge with Asp194, creating a substrate recognition site. The tPA catalytic domain has several features that likely stabilize a functional active site in the singlechain form (sc-tPA, Fig. 3A) . A salt bridge between Lys156 and Asp194 is key to maintaining a functional active site [64] . The carboxylate group of Asp194 forms hydrogen bonds with the main-chain nitrogen atoms of Gly142 and Cys191A that may stabilize the active conformation.
Based on homology with tPA, we became interested in the possibility that fXII has activity in its single chain form (sc-fXII) that could serve as a trigger for contact activation. The glutamine at position 156 in fXII, unlike Lys156 in sc-tPA and singlechain urokinase (sc-uPA), would not form a salt bridge with Asp194 (Fig. 3B ), but it may provide weak stabilization through hydrogen bonding. A homology model of fXII based on the sc-tPA structure suggests fXII Asp194 may also form hydrogen bonds with Gly142 and Cys191A as in sc-tPA (Fig. 3B) [66] . To assess the possibility that sc-fXII is a protease, we prepared and evaluated a form of fXII that cannot be converted to a-fXIIa.
FACTOR XII ACTIVATION
Griffin and Cochrane first raised the question of whether or not a proteolytic event is necessary to achieve fXII activity [67] . Opinions have differed. Silverberg et al. [33, 34] and Tans et al. [35] concluded that a-fXIIa was the active form of fXII, noting that the sigmoidal progress curves for surface-dependent fXII autoactivation best fit a process initiated by a-fXIIa in fXII preparations. However, appreciating the difficulty of eliminating other possibilities with assays based on plasma fXII, Silverberg and Kaplan proposed that sc-fXII might have weak activity. They placed an upper limit on its ability to cleave the tripeptide substrate S-2302 at less than 4200-fold that of a-fXIIa [34] . In contrast, several groups have presented data that suggests the increased activity after fXII binds to a surface does not necessarily require conversion to a-fXIIa [41] [42] [43] . Most recently, Engel et al. [43] showed that fXII binding to the polyanion polyphosphate results in a marked increase in capacity to cleave a tripeptide substrate without obvious conversion to a-fXIIa. As discussed, a potential confounding factor in any study employing plasma fXII is a-fXIIa, either as an initial contaminant or as a product generated during a reaction. To address this, we prepared a recombinant variant of fXII that cannot be converted to a-fXIIa.
FXII is converted to a-fXIIa by autocatalysis, or by proteolysis mediated by a-kal or fXIa (a homolog of a-kal). During activation, the 80 kDa fXII polypeptide is cleaved, resulting in a 50 kDa noncatalytic heavy chain and a 30 kDa catalytic domain connected by a disulfide bond (Fig. 2) [14] . FXII is cleaved at up to three sites within a 20 amino acid span during activation (after Arg334, Arg343, and/or Arg353, Fig. 2 ). Cleavage after Arg353 (equivalent to Arg16 in chymotrypsin numbering, see previous section), converts fXII to a-fXIIa, while subsequent cleavage after Arg334 releases the heavy chain, forming b-FXIIa (Fig. 2) [13,59 ,68]. The consequences of cleavage after Arg343 are not clear. To test the hypothesis that sc-fXII is a protease, we replaced Arg334, Arg343, and Arg353 with alanine [69 && ]. The resulting protein, designated fXII-T (for 'triple' mutant), does not undergo autocatalysis to a-fXIIa in the presence of polyphosphate, and is resistant to cleavage by a-kal and fXIIa.
THE ACTIVITY OF FXII-T
We studied fXII-T activation of the a-fXIIa substrates PPK, fXII itself, and factor XI (fXI), the precursor of fXIa. When wild-type fXII (fXII-WT) is mixed with PPK at plasma concentrations there is reciprocal conversion of the proteins to a-fXIIa and a-kal (Fig. 4A) [69 && ,70] . Initiation of this process is often attributed to traces of a-fXIIa in fXII preparations. However, when fXII-WT is replaced by fXII-T, PPK is still converted to a-kal, although at a lower rate than with fXII-WT [69 && ]. PPK activation by fXII-T turns out to be four orders of magnitude slower than with a-fXIIa. The reaction requires a functional fXII catalytic apparatus, as fXII lacking the key active site serine residue Ser544 (fXII-S544A) [59] does not activate PPK (Fig. 4A) . These data show that sc-fXII has proteolytic activity even in the absence of a cofactor/surface. However, as expected with a contact reaction, PPK activation by fXII-T is accelerated by polyphosphate (Fig. 4B) . Most PPK in plasma circulates in complex with HK [11] , which enhances surface-dependent PPK activation by afXIIa. In preliminary studies we observed that kininogen also enhances fXII-T activation of PPK in the presence of polyphosphate.
FXII undergoes autoactivation to a-fXIIa in the presence of polyphosphate (Fig. 4C) [14] . We wanted to determine if fXII-T catalyzes this reaction, but could not use fXII-WT as a substrate as it autoactivates on its own. Instead we use fXII-S544A, which is cleaved after Arg353 to form the equivalent of afXIIa, but lacks activity once cleaved because of the absence of the active site serine. In Fig. 4D , conversion of fXII-S544A to fXIIa-S544A is followed by western blot using an antibody specific for the fXIIa active site [70] . The a-fXIIa signal increases with time in the presence of silica or polyphosphate, consistent with fXII-T cleaving fXII-S544A after Arg353.
Finally, a-fXIIa promotes coagulation by converting fXI to fXIa by a process accelerated by polyanions [12, 71] . Like fXII, fXI undergoes autoactivation if polyphosphate is present [72] , so we tested the ability of fXII-T to cleave fXI lacking an active site serine (fXI-S557A) to take autoactivation out of the equation [73] . FXII-T cleaves fXI-S557A to a form that migrates with fXIa on Western blot analysis (Fig. 4E) . The prolonged aPTT clotting time of fXII-deficient plasma (327 AE 30 s) is restored to normal by adding fXII-WT (40 AE 2 s). FXII-T had a measurable effect on the aPTT (164 AE 19, P < 0.0001), whereas fXII-S544A (which lacks a functional active site) did not (302 AE 6 s, P ¼ 0.2), consistent with the premise that fXII-T has proteolytic activity that can convert fXI to fXIa.
CONCLUSION AND FUTURE CONSIDERATIONS
In standard models of plasma coagulation used in clinical laboratories, thrombin generation is initiated either by contact activation (the intrinsic pathway of coagulation) or by the factor VIIa/tissue factor complex (the extrinsic pathway). The trigger for the extrinsic pathway seems clear, as up to 4% of factor VII in plasma is in the form of the protease factor VIIa [74] . Although coagulation through the intrinsic pathway begins with fXII activation, the mechanism that initiates the process has been uncertain. The data presented here suggest that fXII expresses sufficient proteolytic activity in its singlechain form to initiate surface-dependent contact activation [69 && ]. Given the low level of activity relative to a-fXIIa, sc-fXII activity is probably most important early in contact activation. As a-fXIIa and a-kal accumulate they would quickly dominate the process, and are almost certainly responsible for the physiologic and pathologic effects of fXII and PPK. Our findings do not exclude other mechanisms for initiating fXII activation. However, the data do indicate that preexisting a-fXIIa is not a requirement.
Polyphosphate enhances fXII-T activation of macromolecular substrates, but fXII-T demonstrates activity even in the absence of this polyanion. FXII-T cleaves the tripeptide S-2302 with $3000-fold lower catalytic efficiency than a-fXIIa [69 && ], a value in reasonable agreement with the maximum for Single-chain factor XII Ivanov et al.
sc-fXII predicted earlier by Silverberg and Kaplan [34] . Interestingly, in contrast to results reported for plasma fXII [43] , polyphosphate did not increase fXII-T cleavage of S-2302 [69 && ]. Taken as a whole, these data indicate that the catalytic domain in scfXII is in an active conformation while circulating (unbound) in plasma that is not as efficient catalytically as that of a-fXIIa. FXII-T also activates PPK in the absence of polyphosphate. Here, binding to a macromolecular substrate may contribute to formation of a functional (or more active) sc-fXII active site, as has been reported for other proteasesubstrate interactions [75] . The cofactor effect provided by polyphosphate, silica and other 'surfaces' may enhance sc-fXII activity by altering the conformation of the protease, the substrate, or both, and also likely serves to concentrate enzymes and substrates, promoting catalysis.
Our findings have some interesting physiologic and pathologic implications. There appears to be a measurable basal rate of reciprocal FXII and PPK activation in healthy mice [36] . Although activation of PPK by fXII-T is several orders of magnitude less efficient than activation by a-fXIIa, the plasma PPK concentration ($600 nM) is near Km for activation by fXII-T, and the plasma fXII concentration ($400 nM) is likely several orders of magnitude higher than that of a-fXIIa under most circumstances. The high plasma fXII level may compensate for the weak specific activity of sc-fXII toward PPK, and the reaction could contribute to fXII and PPK turnover in vivo. The effect of PPK activation by this mechanism is probably limited by serpins such as C1-inhibitor that neutralize a-kal and fXIIa shortly after they form. In addition, we observed that fXII-T cleavage of PPK is inhibited by C1-inhibitor, suggesting sc-fXII activity toward PPK is controlled under normal circumstances. However, the reaction may contribute to the disease process in patients with hereditary angioedema who lack C1-inhibitor [76] . Clinical use of implantable devices and extracorporeal circuits present foreign surfaces to blood that can lead to thromboembolic events and inflammation [5 & ,26,27-31] . Contact activation appears to play a role in complications associated with such devices, and it will be interesting to see if the materials they are made of potentiate the activity of sc-fXII in a manner similar to polyphosphate and silica.
Finally, the observation that fXII has proteolytic activity raises questions of terminology. The current nomenclature system for plasma coagulation factors uses Roman numerals to indicate unactivated forms of coagulation proteins, and Roman numerals followed by a lower case 'a' to indicate forms converted to active species by proteolysis [77, 78] . By this convention, the term fXIIa indicates species of fXII cleaved after Arg353 (a-fXIIa, b-fXIIa), distinguishing them from uncleaved fXII. Given its measurable proteolytic activity, fXII could be considered a form of fXIIa, however, this would not be consistent with the rules of the current system. Perhaps the designation sc-fXII, following the convention for sc-tPA and sc-uPA, may be preferable, at least when discussing protease enzymology.
